Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now?

Is INDV a good stock to buy? We came across a bullish thesis on Indivior Pharmaceuticals, Inc. on The Mispricing Desk’s Substack. In this article, we will summarize the bulls’ thesis on INDV. Indivior Pharmaceuticals, Inc.’s share was trading at $37.39 as of June 8th. INDV’s trailing and forward P/E were 19.30 and 12.27 respectively according to Yahoo Finance.

Copyright: zneb076 / 123RF Stock Photo

Indivior (INDV) is a specialty pharmaceutical company anchored by its SUBLOCADE franchise, which continues to drive accelerating fundamentals and cash generation. On April 30, 2026, Indivior raised full-year guidance to $1.215–$1.285 billion in net revenue and $620–$660 million in adjusted EBITDA after reporting Q1 revenue of $317 million, up 19% YoY, and adjusted EBITDA of $164 million, up 112%. SUBLOCADE remains the core growth engine with $232 million in revenue, up 32%, supported by expanding adoption and over 500,000 cumulative patients treated.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Despite discontinuing two pipeline programs following mixed clinical outcomes, the market continues to anchor on pipeline disappointment rather than improving profitability, stronger execution, and capital return acceleration. Within days of the guidance raise, Indivior announced a $175 million accelerated share repurchase scheduled for completion by end-June 2026, following $125 million of buybacks in Q1, implying over 6% share count reduction and reinforcing a clear shift toward shareholder value creation.

The equity still trades at roughly 8.3x midpoint 2026 EBITDA, while short interest above 11% of float reflects lingering skepticism around sustainability. However, the setup increasingly reflects a rerating opportunity as EBITDA scales, leverage remains contained, and buybacks materially enhance per-share economics. Management’s pivot away from low-return pipeline investment toward disciplined capital allocation strengthens visibility into earnings durability and free cash flow conversion.

With net debt manageable and SUBLOCADE continuing to expand, the catalyst path centers on ASR settlement mechanics and ongoing earnings validation. If sentiment normalizes, rerating toward 9–10x EBITDA implies meaningful upside, while downside appears supported near $35 given de-risked guidance and active capital returns. Indivior increasingly resembles a self-funding compounder mispriced due to legacy pipeline concerns rather than current operating momentum and accelerating shareholder yield.

Previously, we covered a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) by Kontra in April 2025, which highlighted margin expansion, branded drug growth, biosimilar catalysts, and a re-rating driven by cost optimization and resolved litigation. TEVA’s stock price has appreciated by approximately 138.59% since our coverage. The Mispricing Desk shares a similar view but emphasizes near-term capital allocation dynamics and buyback-driven per share value accretion rather than long-term pipeline and structural margin recovery.

Indivior Pharmaceuticals, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held INDV at the end of the first quarter which was 45 in the previous quarter. While we acknowledge the risk and potential of INDV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INDV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

Disclosure: None.